Oxurion’s DME therapy shows positive phase 1 results

THR-687, a diabetic macular edema treatment candidate, was shown to be safe and well tolerated in a phase 1 trial, Oxurion announced in a press release.
The open-label, multicenter, single dose escalation study evaluated the safety of a single intravitreal injection of three increasing doses (0.4 mg, 1 mg and 2.5 mg) of THR-687, a novel pan-RGD integrin antagonist.
Patients in all dosing groups experienced improvement in mean best corrected visual acuity after a single injection. Mean BCVA improved 3.1 letters on day 1, with 9.2 letters of improvement recorded (Read more...)

Full Story →